The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer Jiajing CaiQi QiRong Xia Review – Cancer Research 08 April 2019 Pages: 1377 - 1385
Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer Xiao ZhangYukuan FengXiaobo Li Review – Cancer Research 29 April 2019 Pages: 1387 - 1403
NOD1 and NOD2 of the innate immune system is differently expressed in human clear cell renal cell carcinoma, corresponding healthy renal tissue, its vasculature and primary isolated renal tubular epithelial cells Lilli MeyMichaela JungAnja Urbschat Original Article – Cancer Research 22 March 2019 Pages: 1405 - 1416
Chemopreventive effect of Callistemon citrinus (Curtis) Skeels against colon cancer induced by 1,2-dimethylhydrazine in rats Alejandro López-MejiaLuis Gerardo Ortega-PérezPatricia Rios-Chavez Original Article – Cancer Research 28 March 2019 Pages: 1417 - 1426
ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data Young Wha KohJae-Ho HanJoonho Jung Original Article – Cancer Research 28 March 2019 Pages: 1427 - 1436
Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively Angélica María Gamboa-CedeñoMariángeles CastilloStella Maris Ranuncolo Original Article – Cancer Research 02 April 2019 Pages: 1437 - 1448
Molecular and cellular adaptations to exercise training in skeletal muscle from cancer patients treated with chemotherapy Andreas Buch MøllerSimon LønbroNiels Jessen Original Article – Cancer Research 09 April 2019 Pages: 1449 - 1460
Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration Abdulhameed Al-GhabkariDeema O. QasrawiAru Narendran Original Article – Cancer Research 21 April 2019 Pages: 1461 - 1469
IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2 Xiaodong ChenFeng ChenYuhchyau Chen Original Article – Cancer Research 24 April 2019 Pages: 1471 - 1484
Different statistical techniques dealing with confounding in observational research: measuring the effect of breast-conserving therapy and mastectomy on survival Marissa C. van MaarenSaskia le CessieSabine Siesling Original Article – Cancer Research 24 April 2019 Pages: 1485 - 1493
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy Erlend SkagaIda Ø. SkagaEinar O. Vik-Mo Original Article – Cancer Research Open access 26 April 2019 Pages: 1495 - 1507
TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells Jinfang ZhuWeiran LiuChangli Wang Original Article – Cancer Research 23 April 2019 Pages: 1509 - 1519
Research driving innovation: what are key factors for successful integration of translational science into oncology care concepts? 5th European Roundtable Meeting (ERTM) May 4th, 2018, Berlin, Germany Olaf OrtmannJulie TorodeFor the Participants of the ERTM Review – Clinical Oncology 16 April 2019 Pages: 1521 - 1525
Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases Suheil Albert Atallah-YunesAnis John KadadoJaime Hernandez-Montfort Review – Clinical Oncology 26 April 2019 Pages: 1527 - 1557
Gastrointestinal stromal tumors (GISTs) with remarkable cystic change: a specific subtype of GISTs with relatively indolent behaviors and favorable prognoses Anwei XueWei YuanKuntang Shen Original Article – Clinical Oncology Open access 28 March 2019 Pages: 1559 - 1568
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression Martin SchulerEng-Huat TanKeunchil Park Original Article - Clinical Oncology Open access 19 February 2019 Pages: 1569 - 1579
Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter? Vérane AchardSandra JorcanoThomas Zilli Original Article – Clinical Oncology 18 March 2019 Pages: 1581 - 1588
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia Jorge E. CortesCarlo Gambacorti-Passerinithe BFORE Study Investigators Original Article – Clinical Oncology 15 April 2019 Pages: 1589 - 1599
Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma Nidhi GuptaRaman KumarAlpana Sharma Original Article – Clinical Oncology 19 March 2019 Pages: 1601 - 1611
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice Beung-Chul AhnKyoung-Ho PyoHye Ryun Kim Original Article – Clinical Oncology Open access 25 March 2019 Pages: 1613 - 1623
Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer Fan LianWenchuan ChenYu Wang Original Article – Clinical Oncology 21 March 2019 Pages: 1625 - 1633
Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer Peter G. HawkinsYilun SunShruti Jolly Original Article – Clinical Oncology 28 March 2019 Pages: 1635 - 1643
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry) Susanne MöbiusThomas SchenkThomas Ernst Original Article – Clinical Oncology 02 April 2019 Pages: 1645 - 1650
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva Fabinshy ThangarajahBernd MorgensternAnne Maria Schultheis Original Article – Clinical Oncology 10 April 2019 Pages: 1651 - 1660
Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy Kosuke MizutaniKengo HorieMasafumi Ito Letter to the Editors Open access 05 December 2018 Pages: 1661 - 1663